1. Home
  2. COEP vs LSTA Comparison

COEP vs LSTA Comparison

Compare COEP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • LSTA
  • Stock Information
  • Founded
  • COEP 2017
  • LSTA 1980
  • Country
  • COEP United States
  • LSTA United States
  • Employees
  • COEP N/A
  • LSTA N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • COEP Health Care
  • LSTA Health Care
  • Exchange
  • COEP Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • COEP 27.4M
  • LSTA 24.1M
  • IPO Year
  • COEP N/A
  • LSTA N/A
  • Fundamental
  • Price
  • COEP $9.60
  • LSTA $2.91
  • Analyst Decision
  • COEP
  • LSTA Strong Buy
  • Analyst Count
  • COEP 0
  • LSTA 1
  • Target Price
  • COEP N/A
  • LSTA $15.00
  • AVG Volume (30 Days)
  • COEP 33.0K
  • LSTA 21.4K
  • Earning Date
  • COEP 08-15-2025
  • LSTA 08-11-2025
  • Dividend Yield
  • COEP N/A
  • LSTA N/A
  • EPS Growth
  • COEP N/A
  • LSTA N/A
  • EPS
  • COEP N/A
  • LSTA N/A
  • Revenue
  • COEP $62,874.00
  • LSTA $1,000,000.00
  • Revenue This Year
  • COEP N/A
  • LSTA N/A
  • Revenue Next Year
  • COEP N/A
  • LSTA N/A
  • P/E Ratio
  • COEP N/A
  • LSTA N/A
  • Revenue Growth
  • COEP N/A
  • LSTA N/A
  • 52 Week Low
  • COEP $2.31
  • LSTA $1.87
  • 52 Week High
  • COEP $13.70
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • COEP 58.28
  • LSTA 59.12
  • Support Level
  • COEP $7.25
  • LSTA $2.34
  • Resistance Level
  • COEP $8.86
  • LSTA $3.09
  • Average True Range (ATR)
  • COEP 0.63
  • LSTA 0.26
  • MACD
  • COEP 0.14
  • LSTA 0.02
  • Stochastic Oscillator
  • COEP 99.55
  • LSTA 76.00

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: